EVEROLD 2014.

Methods	Design: open‐label RCT Duration: not reported Follow up: 1 year
Participants	Setting: national multi‐centre study Country: France Participants: 1st or 2nd single transplantation of a recipient > 60 years, donor > 60 years, low immunological risk (PRA < 30%) Number: 304 enrolled; 285 analysed Mean age ± SD (years): not reported Sex (M/F): not reported Exclusions: LD; 3rd transplantation; PRA > 30%
Interventions	Treatment group 1 CSA: 6 to 8 mg/kg/d adjusted for C2 levels MMF: 3 g/d IL2 induction Treatment group 2 EVL: 4 to 6 mg/d from day 5 MMF: 3 g/d ATG induction Treatment group 3 Switch to EVL at week 7 CSA till end of week 6 IL2 induction MMF Co‐interventions Steroids
Outcomes	Patient survival Graft loss DGF BPAR GFR (MDRD) Discontinuation Adverse events
Notes	M‐TOR versus CNI (compared groups 1 and 2) No information on numbers in each group so data could not be entered into meta‐analyses No response from email to authors
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Said to be randomised but no other information provided.
Allocation concealment (selection bias)	Unclear risk	Said to be randomised but no other information provided.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open‐label study
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Primary outcomes unlikely to be influenced by lack of blinding.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Reported on 94% of participants.
Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgement ‐ abstract only
Other bias	High risk	Novartis, Roche, Genzyme listed on clinical trials as sponsors